Get the Stockscreener App
3.39
4.95%
0.16
After Hours:
3.39
Scisparc Ltd stock is traded at $3.39, with a volume of 7,839.
It is up +4.95% in the last 24 hours and down -22.25% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$3.23
Open:
$3.33
24h Volume:
7,839
Relative Volume:
0.05
Market Cap:
$1.92M
Revenue:
$927.00K
Net Income/Loss:
$-13.21M
P/E Ratio:
-0.0161
EPS:
-210.8843
Net Cash Flow:
$-4.77M
1W Performance:
-0.88%
1M Performance:
-22.25%
6M Performance:
-91.22%
1Y Performance:
+30.79%
1-Day Range:
$3.2537
$3.40
1-Week Range:
$2.98
$3.40
52-Week Range:
$2.2644
$80.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
3.39 | 1.83M | 927.00K | -13.21M | -4.77M | -210.88 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scisparc Ltd Stock (SPRC) Latest News
Block Trades: Can SciSparc Ltd scale operations efficientlyQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Institution Moves: Can SciSparc Ltd outperform in the next rallyEntry Point & Community Verified Swing Trade Signals - baoquankhu1.vn
Market Trends: What makes SciSparc Ltd stock attractive todayOptions Play & Safe Entry Point Alerts - baoquankhu1.vn
MACD Signal: Is SciSparc Ltd impacted by rising ratesWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Institution Moves: Is SciSparc Ltd impacted by rising rates2026 Drop Watch & Breakout Confirmation Alerts - baoquankhu1.vn
Buyback Watch: Can SciSparc Ltd outperform in the next rallyWeekly Trade Analysis & Smart Allocation Stock Tips - baoquankhu1.vn
SPRC Should I Buy - Intellectia AI
SPRC Technical Analysis | Trend, Signals & Chart Patterns | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SPRC Stock Price, Quote & Chart | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Whale Trades: How correlated is SciSparc Ltd to the S P5002026 Macro Impact & Entry Point Confirmation Alerts - baoquankhu1.vn
SciSparc (SPRC) director Dayan Alon reports 3,651-share ownership stake - Stock Titan
SPRC SEC FilingsScisparc 10-K, 10-Q, 8-K Forms - Stock Titan
SciSparc (SPRC) director discloses shares, options and RSU awards - stocktitan.net
SciSparc (SPRC) director reports initial share and option holdings - Stock Titan
SciSparc (SPRC) director Revach Moshe discloses initial share and RSU holdings - Stock Titan
SciSparc (SPRC) CEO Adler Oz details share, option and RSU holdings - Stock Titan
SciSparc (SPRC) director Weiss Amitay details equity holdings - Stock Titan
SciSparc (SPRC) director Vider Lior details shares, options and RSUs - Stock Titan
SciSparc (SPRC) CTO details 5,528 Ordinary Shares and option holdings on Form 3 - Stock Titan
SciSparc (SPRC) director reports 3,651-share stake and RSU grants - Stock Titan
Sentiment Watch: Can SciSparc Ltd stock outperform in a bear marketRecession Risk & Expert Verified Stock Movement Alerts - baoquankhu1.vn
SciSparc stock rallies after AutoMax files motion on pending merger - MSN
Buyout Rumor: Is SciSparc Ltd impacted by rising ratesMarket Performance Report & Low Drawdown Investment Ideas - baoquankhu1.vn
SciSparc subsidiary files patent for depression treatment By Investing.com - Investing.com India
[SCHEDULE 13G] SciSparc Ltd. Passive Investment Disclosure (>5%) - Stock Titan
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
Eli Zamir reports ≤5% stake in SciSparc (NASDAQ: SPRC) - Stock Titan
SciSparc (NASDAQ: SPRC) collaboration advances MEAI-PEA depression patent bid - Stock Titan
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
SciSparc subsidiary files patent for depression treatment - Investing.com
SciSparc Ltd. Reports NeuroThera Labs' Patent Application for Innovative Depression Treatment Combining MEAI and PEA - quiverquant.com
SciSparc Subsidiary NeuroThera to Take Majority Stake in Quantum Trials Firm CliniQuantum - TipRanks
SciSparc (Nasdaq: SPRC) unit to acquire 54% of CliniQuantum and lose NeuroThera control - Stock Titan
SciSparc’s Neurothera Labs announces publication of international patent - TipRanks
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
SciSparc: $9.46 Million NeuroThera Deal To Acquire Majority Stake In Quantum Clinical Trials Firm CliniQuantum - Pulse 2.0
SciSparc, Subsidiary NeuroThera Labs Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - marketscreener.com
NeuroThera to acquire 54% stake in quantum tech firm CliniQ By Investing.com - Investing.com South Africa
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails - Bitget
SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum - TipRanks
SciSparc Ltd. Subsidiary NeuroThera Labs Inc. Enters Share Purchase Agreement to Acquire Majority Stake in CliniQuantum Ltd. - Quiver Quantitative
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd. - TheNewswire
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd. (2026-03-10) - Seeking Alpha
SciSparc Ltd. (SPRC) Schedule 13G/A amendment shows holder ≤5% - Stock Titan
Can SciSparc Ltd. stock resist market sell offsJuly 2025 Update & Accurate Trade Setup Notifications - Naître et grandir
Aug Reactions: What is the implied volatility of SciSparc LtdEarnings Summary Report & Fast Gain Stock Trading Tips - baoquankhu1.vn
Analyst Upgrade: Whats the beta of SciSparc Ltd stockPortfolio Update Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
SciSparc announces publication of Japanese patent application - MSN
SPRC Earnings History & Surprises | EPS & Revenue Results | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):